Risk of autoimmune hepatitis reactivation in patients with chronic hepatitis C and autoimmune hepatitis treated with direct-acting antivirals

Pol Arch Intern Med. 2019 Mar 29;129(3):215-218. doi: 10.20452/pamw.4442. Epub 2019 Feb 13.

Authors

Katarzyna Fleischer-Stępniewska¹, Weronika Rymer¹, Marcin S Inglot², Małgorzata Zalewska¹, Brygida Knysz¹, Małgorzata Inglot¹

Affiliations

¹ Department of Infectious Diseases, Liver Diseases and Acquired Immune Deficiences, Wroclaw Medical University, Wrocław, Poland.
² Department of General and Pediatric Radiology, Wroclaw Medical University, Wrocław, Poland.

PMID: 30758316
DOI: 10.20452/pamw.4442

No abstract available

Publication types

Letter
Observational Study

MeSH terms

Adult
Anti-Inflammatory Agents / therapeutic use
Antiviral Agents / therapeutic use*
Female
Hepatitis C, Chronic / drug therapy*
Hepatitis C, Chronic / immunology
Hepatitis, Autoimmune / drug therapy*
Hepatitis, Autoimmune / immunology
Humans
Male
Middle Aged
Prospective Studies
Risk Factors
Treatment Outcome
Virus Activation / drug effects*

Substances

Anti-Inflammatory Agents
Antiviral Agents